Stock Detail
Sector:
Latest Quote @ Tue May 5 06:27:20 (15 min delayed)
Last Day's Data
| $0.00 |
$0.00 |
$0.00 |
0.00% |
0.00 |
$0.00 |
| $0.00 |
$0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Stock Profile
Human Genome Sciences, Inc. operates as a biopharmaceutical company with a pipeline of novel protein and antibody drugs. The company's drugs in clinical development include LymphoStat-BTM for the treatment of lupus and rheumatoid arthritis; AlbuferonTM for the treatment of chronic hepatitis C; HGS-ETR1, HGS-ETR2, HGS-TR2J for the treatment of solid and hematopoietic cancers; CCR5 mAb for the treatment of HIV/ AIDS; and ABthraxTM for the treatment of anthrax infection. It has various strategic partners, including GlaxoSmithKline, Takeda, Schering-Plough, Sanofi-Synthelabo, Merck KGaA, Transgene, MedImmune, Inc., and Pharmacia & Upjohn. Human Genome Sciences was founded in 1992 and is headquartered in Rockville, Maryland.
